t
Hikma Pharmaceuticals PLC announced on 22 September 2026 that it will host a series of three educational investor seminars focusing on its R&D strategy and capabilities, aspiring to spend 5% to 6% of revenue on R&D going forward. These seminars are scheduled for 20 October, 24 November, and 16 December 2026, and will not provide new material financial or trading information.
| Date | 22 Sept 2026 |
| Time | 12:00:01 |
| Category | Miscellaneous |
| ID | 8163V |
Hikma R&D Investor Spotlight Series
London, Tuesday 22 September 2026 - Hikma Pharmaceuticals PLC ('Hikma' or 'Group'), the multinational pharmaceutical company, today announces it will host a series of three educational investor seminars on the Group's R&D strategy and capabilities.
Hikma is committed to increasing investment in R&D and aspires to spend around 5% to 6% of revenue on R&D going forward. The series will demonstrate how Hikma is strengthening its global pipeline to support the long-term growth of the business, with the right people, capabilities and vision in place to succeed. Each seminar will focus on one of the Hikma's three key R&D pillars:
- 20th October 2026, 14:00 BST: Group R&D and Respiratory, Nasal, Semi-Solids and Liquids
- 24th November 2026, 14:00 GMT: Solid Orals
- 16th December 2026, 14:00 GMT: Injectables
The hour-long sessions will be educational in nature, and no new material financial or trading information will be provided.
The next scheduled update on trading will be on 5 November 2026, in line with the Group's normal reporting timetable.
Registration is now open using the links below:
- Group R&D and Respiratory, Nasal, Semi-Solids and Liquids: https://sparklive.lseg.com/HikmaPharmaceuticals/events/9461f4bc-0235-4587-b4ef-b3ae1cf329cc/hikma-pharmaceuticals-r-d-spotlight-series-respiratory-nasal-semi-solids-liquids
A recording of each event will be made available on the Company's website.
Enquiries
Hikma (Investors):
|
Susan Ringdal EVP, Strategic Planning and Global Affairs
|
+44 (0)20 7399 2760/ +44 (0)7776 477050 |
|
Guy Featherstone Sr Director, Global Investor Relations
|
+44 (0)20 3892 4389/ +44 (0)7795 896738 |
|
Veronica Farah Associate, Investor Relations |
+ 44 (0) 7795 911385 |
About Hikma:
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)